drugset / Trial / NCT04981665
A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection
Phase 2
Unknown
50 enrolled
Zhejiang University
First Hospital of China Medical University · collabHainan People's Hospital · collabShandong Cancer Hospital and Institute · collabThe Affiliated Hospital Of Southwest Medical University · collabTianjin Third Central Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This is an open label, multi-center, phaseⅡstudy to evaluate the efficacy and safety of TACE sequential tislelizumab as adjuvant therapy in hepatocellular carcinoma (HCC) patients who are at high risk of recurrence after curative resection.
Timeline
- Start
- 2021-11-08
- Primary completion
- 2024-12
- Completion
- 2024-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | Intravenous |